FL-AMGTA
24.4.2024 14:00:35 CEST | Business Wire | Press release
The Additive Manufacturer Green Trade Association (“AMGTA”) a global advocacy group focused on promoting sustainable additive manufacturing (“AM”) industry practices, announced today the preliminary results of a research project titled “Specific Energy of Metal AM Feedstock: A Comparison.” The study, commissioned by the AMGTA and conducted by Syntec Associates, a research consultancy, in partnership with Divergent Technologies, a complete modular digital factory for complex structures, evaluated three key metal AM feedstock processing approaches—gas atomization, mechanical milling (specifically ball milling), and wire drawing—to determine specific energy requirements for producing feedstock materials. The research findings highlighted that, from an energy perspective, helium gas atomization is the most sustainable method used for gas atomization for metallic powder production of commonly used alloys, followed by argon and then nitrogen. Specific energy consumption for atomization also critically depends on process parameters and alloy chemistry. Additionally, research showed that mechanical milling, when appropriate for use in powder production in additive manufacturing, exhibits a significant reduction in specific energy consumption when compared to gas atomization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416215703/en/
Photo courtesy of Carpenter Additive
“When preparing life cycle assessments on industrial rate processing of our alloys, I found wide variation in the literature on AM process and powder atomization energy consumption,” said Michael Kenworthy, Chief Technology Officer at Divergent Technologies and AMGTA Board Director. “This research established a transparent set of process assumptions and models from which to understand the key process levers and evaluate system trade studies that inform future sustainability enhancements.”
Key takeaways from this study include:
- Helium Gas Atomization is Best for Powder Atomization: Research indicates that, from an energy perspective, helium gas atomization stands out as the most sustainable gas atomization method, showing a significant reduction in specific energy consumption compared to argon and nitrogen for commonly used alloys.
- Argon Atomized Powder is Better than Nitrogen: For those seeking an alternative to helium, argon-atomized powder is revealed to be a notable option, energy savings when compared to nitrogen-atomized powder.
- Mechanical Milling Outperforms Gas Atomization: Mechanical milling, particularly ball milling, demonstrates a significant reduction in specific energy consumption compared to gas atomization for metal AM powder production.
- Industry Guidance for Sustainable Choices: This research highlights the importance of selecting manufacturing methods with the lowest specific energy consumption per kilogram to enhance overall sustainability when producing feedstock materials used in additive manufacturing.
“A primary goal of the AMGTA is to educate the consumer on the most sustainable methods of production within the additive supply chain. This important piece of research provides guidance on which methods of gas atomization require the least amount of specific energy per kilogram,” said Brian R. Neff, AMGTA’s Board Chair. “At the same time, it indicates to the market that mechanical production methods of powder feedstock, such as ball milling, are themselves an order of magnitude better than gas atomization from an energy perspective.”
Gas atomization, deemed a promising technology for producing stock powders for additive manufacturing, was a focal point of the study. The research revealed that gas atomization using helium as the atomization gas resulted in the least total specific energy consumption compared to argon (13% better on average) and nitrogen (28% better on average). Additionally, argon-atomized powder was found to reduce energy requirements by 12% when compared to nitrogen-atomized powder for the alloys studied (SS316L, Al5083, and IN718).
The study also highlights the efficiency of mechanical powder production, particularly ball milling, which showed approximately a 90% improvement in specific energy consumption compared to gas atomization for the range of process conditions studied. Further research is recommended to determine the applied impact within specific product categories of using helium-atomized powder and/or ball milled powder.
“This research aligns with the AMGTA commitment to better understand sustainable manufacturing practices leveraging additive technologies,” said Sherri Monroe, the AMGTA’s Executive Director. “These findings highlight key considerations for manufacturers seeking environmentally friendly feedstock production methods. To advance sustainability in additive manufacturing, research is vital in order to make informed decisions.”
Highlights from the study can be found on the AMGTA’s website. The AMGTA says it expects to publish additional independent research throughout 2024. Additional information on this study and others conducted by the AMGTA can be found on the AMGTA website, www.AMGTA.org.
About the AMGTA
The AMGTA was launched in 2019 to better understand and promote the environmental benefits of additive manufacturing across the global economy. AMGTA members represent the entirety of the manufacturing spectrum - from design and raw materials to end products and users - focused on innovating better, more sustainable, and financially advantageous products through best additive practices. For more information, please visit www.amgta.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416215703/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
